AWARD
A -- Feasibility Study of a Single Platform Solution for Blood Testing of TBI Biomarkers
- Notice Date
- 9/12/2022 4:23:15 AM
- Notice Type
- Award Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- W4PZ USA MED RSCH ACQUIS ACT FORT DETRICK MD 21702-5014 USA
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-22-C-0059
- Archive Date
- 09/24/2022
- Point of Contact
- Beverly R. Michaels
- E-Mail Address
-
beverly.r.michaels.civ@health.mil
(beverly.r.michaels.civ@health.mil)
- Award Number
- W81XWH-22-C-0059
- Award Date
- 09/09/2022
- Awardee
- GRYPHON BIO INC TX 78215 USA
- Award Amount
- 749437.00
- Description
- Gryphon Bio's novel Single Platform Solution (SPS), combining high frequency dried plasma spot (DPS) sampling with high sensitivity immunoassays of a proprietary panel of blood-based temporal TBI biomarkers (acute, subacute, and chronic), can monitor patients� progression and phenotype individual trajectories to reconstruct and inform on key decisions from the initial injury in the field to hospital and home settings. They have generated striking preliminary data for their SPS using a prototype DPS sampling device from Capitainer and high sensitivity immunoassay platform from Olink which, together with their longitudinal and verification data from traditional �wet� TBI specimens and immunoassay platforms, provides strong evidence for the high probability of success of the proposed �Feasibility Study of a SPS for Blood Testing of TBI Biomarkers�.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/c153ec8d35f64c0fb02ed6c9875ba481/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06460574-F 20220914/220912230116 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |